Goldline Pharmaceutical Limited IPO
Goldline Pharmaceutical Limited was a SME IPO, offered at ₹41–₹43 per share. The issue was subscribed 781.85× overall (QIBs 180.22×, NIIs 1227.9×, retail 881.15×). It listed on 19 May 2026 at ₹60 and closed its first day at ₹57, a listing gain of +32.0% versus the ₹43 issue price. It now trades around ₹31 (-27.4% versus the issue price).
Frequently asked questions
- How many times was the Goldline Pharmaceutical Limited IPO subscribed?
- The Goldline Pharmaceutical Limited IPO was subscribed 781.85× overall — 180.22× in the QIB category, 1227.9× among non-institutional investors, 881.15× in retail.
- What were the Goldline Pharmaceutical Limited IPO listing gains?
- Goldline Pharmaceutical Limited listed on 19 May 2026 at ₹60, closing its first day at ₹57 — a listing gain of +32.0% versus the ₹43 issue price.
- What were the retail allotment odds for the Goldline Pharmaceutical Limited IPO?
- Retail was subscribed 881.15×, so a single-lot application had roughly a 0.1% chance of allotment (about 1 in 881), and allotment was finalised on 15 May 2026.
- What was the price band and lot size of the Goldline Pharmaceutical Limited IPO?
- The price band was ₹41–₹43 per share.